About: Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: $3.23 (-4.15%)
IXHLNASDAQIncannex Healthcare Ltd ADR
Incannex Healthcare Ltd ADR share price
IXHL price activity
Last Price
$3.230
Change (24hr)
-0.14 USD (-4.15%)
Volume
35.96K
Volume (4w avg)
-
Open
$3.33
Day Range
$3.22 - $3.40
Previous Close
$3.37
Last Trade
09 Sep, 8:09 pm GMT+0
Delayed
09 Sep, 8:09 pm GMT+0
IXHL price performance
Delayed
09 Sep, 8:09 pm GMT+0
IXHL Market Signals